PMID- 38015334
OWN - NLM
STAT- MEDLINE
DCOM- 20240110
LR  - 20240112
IS  - 1534-6307 (Electronic)
IS  - 1523-3774 (Print)
IS  - 1523-3774 (Linking)
VI  - 26
IP  - 1
DP  - 2024 Jan
TI  - Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated 
      Vasculitis.
PG  - 12-23
LID - 10.1007/s11926-023-01123-8 [doi]
AB  - PURPOSE OF REVIEW: Anti-neutrophil cytoplasm antibody (ANCA)-associated 
      vasculitis (AAV) is a rare, multisystem, autoimmune disease characterised by 
      microvascular inflammation. Over the past 20 years, advances in immunological 
      management have improved short-term patient outcomes. Longer-term patient 
      outcomes remain poor with cardiovascular disease now the leading cause of death 
      in AAV. Here, we examine the potential pathways that contribute to the increased 
      risk of cardiovascular disease in AAV and the current evidence to manage this 
      risk. RECENT FINDINGS: The incidence of cardiovascular disease in AAV exceeds 
      that expected by traditional risk factors alone, suggesting a contribution from 
      disease-specific factors. Similarly, it is unclear how different 
      immunosuppressive therapies contribute to and modify cardiovascular risk, and 
      there is a paucity of data examining the efficacy of traditional cardioprotective 
      medications in AAV. There is a lack of evidence-based cardiovascular risk 
      assessment tools and cardioprotective therapies in patients with AAV which should 
      be addressed to improve long-term outcomes.
CI  - (c) 2023. The Author(s).
FAU - Sayer, Matthew
AU  - Sayer M
AUID- ORCID: 0000-0001-9618-2221
AD  - Edinburgh Kidney, University/BHF Centre for Cardiovascular Science, The Queen's 
      Medical Research Institute, University of Edinburgh, Edinburgh, UK.
AD  - Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
FAU - Chapman, Gavin B
AU  - Chapman GB
AUID- ORCID: 0009-0002-1266-2151
AD  - Edinburgh Kidney, University/BHF Centre for Cardiovascular Science, The Queen's 
      Medical Research Institute, University of Edinburgh, Edinburgh, UK.
AD  - Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
FAU - Thomas, Matthew
AU  - Thomas M
AUID- ORCID: 0000-0002-8343-7376
AD  - Edinburgh Kidney, University/BHF Centre for Cardiovascular Science, The Queen's 
      Medical Research Institute, University of Edinburgh, Edinburgh, UK.
AD  - Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
FAU - Dhaun, Neeraj
AU  - Dhaun N
AUID- ORCID: 0000-0001-9128-6603
AD  - Edinburgh Kidney, University/BHF Centre for Cardiovascular Science, The Queen's 
      Medical Research Institute, University of Edinburgh, Edinburgh, UK. 
      bean.dhaun@ed.ac.uk.
AD  - Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK. 
      bean.dhaun@ed.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231128
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
SB  - IM
MH  - Humans
MH  - *Cardiovascular Diseases/etiology
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications/drug 
      therapy
MH  - Inflammation/complications
MH  - Risk Factors
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Cytoplasm/metabolism
PMC - PMC10776689
OTO - NOTNLM
OT  - ANCA vasculitis
OT  - Cardiovascular disease
COIS- MS, MT, and GBC declare no competing interests. ND has acted as a consultant for 
      and received research funding for an investigator-initiated study from Travere 
      Therapeutics.
EDAT- 2023/11/28 12:42
MHDA- 2024/01/10 06:42
PMCR- 2023/11/28
CRDT- 2023/11/28 11:12
PHST- 2023/11/06 00:00 [accepted]
PHST- 2024/01/10 06:42 [medline]
PHST- 2023/11/28 12:42 [pubmed]
PHST- 2023/11/28 11:12 [entrez]
PHST- 2023/11/28 00:00 [pmc-release]
AID - 10.1007/s11926-023-01123-8 [pii]
AID - 1123 [pii]
AID - 10.1007/s11926-023-01123-8 [doi]
PST - ppublish
SO  - Curr Rheumatol Rep. 2024 Jan;26(1):12-23. doi: 10.1007/s11926-023-01123-8. Epub 
      2023 Nov 28.